CLLS
Cellectis SANASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$402.36M
P/E Ratio
—
EPS
$-0.67
Beta
2.71
52W High
$5.48
52W Low
$1.33
50-Day MA
$3.71
200-Day MA
$3.64
Dividend Yield
—
Profit Margin
-84.90%
Forward P/E
—
PEG Ratio
0.00
About Cellectis SA
Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors to attack and eradicate cancer cells. The company is headquartered in Paris, France.
Fundamentals
| Revenue (TTM) | $79.59M |
| Gross Profit (TTM) | $79.59M |
| EBITDA | $-21.75M |
| Operating Margin | -142.10% |
| Return on Equity | -65.30% |
| Return on Assets | -5.84% |
| Revenue/Share (TTM) | $0.79 |
| Book Value | $1.05 |
| Price-to-Book | 5.30 |
| Price-to-Sales (TTM) | 5.06 |
| EV/Revenue | 3.928 |
| EV/EBITDA | -3.90 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -19.50% |
| Shares Outstanding | $72.59M |
| Float | $46.68M |
| % Insiders | 0.00% |
| % Institutions | 16.96% |
Historical Volatility
HV 10-Day
64.01%
HV 20-Day
85.30%
HV 30-Day
76.94%
HV 60-Day
73.21%
HV Rank
46.0%
Volatility is currently contracting
Analyst Ratings
Consensus ($7.25 target)
1
Strong Buy2
Buy2
HoldData last updated: 4/29/2026